Chidamide Suppresses the Growth of Cholangiocarcinoma by Inhibiting HDAC3 and Promoting FOXO1 Acetylation
Inhibitors for histone deacetylases (HDACs) have been identified as epigenetic drug targets to treat a variety of malignancies through several molecular mechanisms. The present study is aimed at investigating the mechanism underlying the possible antitumor effect of the HDAC inhibitor chidamide (CDM...
Saved in:
Main Authors: | Yongpan Li, Jujia Zheng, Qiang Huo, Zhongchao Chen, Jun Chen, Xiangwei Xu |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2022-01-01
|
Series: | Stem Cells International |
Online Access: | http://dx.doi.org/10.1155/2022/3632549 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Sodium Valproate Inhibits the Growth of Human Cholangiocarcinoma In Vitro and In Vivo
by: Bing Wang, et al.
Published: (2013-01-01) -
TEC-mediated tRF-31R9J regulates histone lactylation and acetylation by HDAC1 to suppress hepatocyte ferroptosis and improve non-alcoholic steatohepatitis
by: Juanjuan Zhu, et al.
Published: (2025-01-01) -
Upregulation of CD19 by low‐dose chidamide promotes CAR T cells functionality in B-cell non-Hodgkin lymphoma
by: Ying Ni, et al.
Published: (2025-01-01) -
Pathogenic variants of TUBB8 cause oocyte spindle defects by disrupting with EB1/CAKP5 interactions and potential treatment targeting microtubule acetylation through HDAC6 inhibition
by: Hui Luo, et al.
Published: (2025-01-01) -
HDAC Inhibition Modulates Cardiac PPARs and Fatty Acid Metabolism in Diabetic Cardiomyopathy
by: Ting-I Lee, et al.
Published: (2016-01-01)